Statement: A minimum bodyweight of 50kg is required to participate in the primary trial.
Primary_evidence: DISEASE CHARACTERISTICS:   Histologically or cytologically confirmed adenocarcinoma of the breast   Stage III or IV disease   Primary or recurrent disease   Invasive lobular carcinoma allowed   HLA-A1, -A2, -A3, or -A31 positive   Underwent and recovered from prior primary therapy   Patients with no clinical or radiological evidence of disease who had a previous diagnosis of stage III or IV breast cancer must have undergone prior antineoplastic therapy including, but not limited to, surgery, chemotherapy, and radiotherapy within the past 36 months   Must have at least one undissected axillary and/or inguinal lymph node basin   No history of brain metastases   Hormone receptor status   Estrogen receptor-positive or -negative tumor   PATIENT CHARACTERISTICS:   ECOG performance status of 0 or 1   Body weight > 110 lbs (without clothes)   Male or female   Menopausal status not specified   Absolute neutrophil count > 1000/mm^3   Platelet count > 100,000/mm^3   Hemoglobin > 9 g/dL   Hemoglobin A1c < 7%   AST and ALT  2.5 x upper limit of normal (ULN)   Bilirubin  2.5 x ULN   Alkaline phosphatase  2.5 x ULN   Creatinine  1.5 x ULN   HIV negative   Hepatitis C negative   Not pregnant or nursing   Negative pregnancy test   Fertile patients must use effective contraception   No known or suspected allergies to any component of the vaccine   No active infection requiring antibiotics   No New York Heart Association class III or IV heart disease   No autoimmune disorders requiring cytotoxic or immunosuppressive therapy or autoimmune disorders with visceral involvement, except the following:   Laboratory evidence of autoimmune disease (e.g., positive ANA titer) without symptoms   Clinical evidence of vitiligo   Other forms of depigmenting illness   Mild arthritis requiring nonsteroidal antiinflammatory drugs   No medical contraindication or potential problem that would preclude study participation   PRIOR CONCURRENT THERAPY:   More than 4 weeks since prior surgery   More than 4 weeks since prior and no concurrent chemotherapy and radiotherapy   More than 4 weeks since prior and no concurrent allergy desensitization injections   More than 4 weeks since prior parenteral, oral, or inhaled corticosteroids   No concurrent inhaled steroids (e.g., Advair® or triamcinolone acetonide)   Prior or concurrent topical corticosteroids allowed   More than 4 weeks since prior and no concurrent growth factors (e.g., epoetin alfa, darbepoetin alfa, or pegfilgrastim)   More than 4 weeks since prior and no concurrent other investigational medication   More than 4 weeks since prior and no concurrent other agents with putative immunomodulating activity except for non-steroidal anti-inflammatory agents   Prior and concurrent hormonal therapy (e.g., tamoxifen, raloxifene, toremifene, fulvestrant, letrozole, anastrozole, or exemestane) allowed   No prior vaccination with any synthetic peptides in this protocol   Vaccines for infectious disease (e.g., influenza) allowed, provided they are administered  2 weeks prior to or  2 weeks after study vaccine   Short term therapy for acute conditions not related to breast cancer allowed   No concurrent illegal drugs